[go: up one dir, main page]

WO2006089150A3 - Antiangiogenic agents with aldesleukin - Google Patents

Antiangiogenic agents with aldesleukin Download PDF

Info

Publication number
WO2006089150A3
WO2006089150A3 PCT/US2006/005720 US2006005720W WO2006089150A3 WO 2006089150 A3 WO2006089150 A3 WO 2006089150A3 US 2006005720 W US2006005720 W US 2006005720W WO 2006089150 A3 WO2006089150 A3 WO 2006089150A3
Authority
WO
WIPO (PCT)
Prior art keywords
aldesleukin
antiangiogenic agents
compositions
antiangiogenic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/005720
Other languages
French (fr)
Other versions
WO2006089150A2 (en
Inventor
Sharon Lea Aukerman
Kimberly Denis-Mize
Laurence Elias
Bahija Jallal
Daniel Menezes
Gary W Witherell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP06735400A priority Critical patent/EP1853302A2/en
Priority to JP2007556337A priority patent/JP2008530239A/en
Priority to AU2006214138A priority patent/AU2006214138A1/en
Priority to BRPI0608880-5A priority patent/BRPI0608880A2/en
Priority to CA002598448A priority patent/CA2598448A1/en
Priority to MX2007010037A priority patent/MX2007010037A/en
Publication of WO2006089150A2 publication Critical patent/WO2006089150A2/en
Publication of WO2006089150A3 publication Critical patent/WO2006089150A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to combination therapies with IL-2 compositions and antiangiogenic agents for the treatment of cancer. Further provided are methods of alleviating toxicities and increasing the efficacy associated with the administration of IL-2 compositions or antiangiogenic compositions.
PCT/US2006/005720 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin Ceased WO2006089150A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06735400A EP1853302A2 (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin
JP2007556337A JP2008530239A (en) 2005-02-18 2006-02-17 Anti-angiogenic agents containing aldesleukin
AU2006214138A AU2006214138A1 (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin
BRPI0608880-5A BRPI0608880A2 (en) 2005-02-18 2006-02-17 anti-angiogenic agents with aldesleukin
CA002598448A CA2598448A1 (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin
MX2007010037A MX2007010037A (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65434105P 2005-02-18 2005-02-18
US60/654,341 2005-02-18

Publications (2)

Publication Number Publication Date
WO2006089150A2 WO2006089150A2 (en) 2006-08-24
WO2006089150A3 true WO2006089150A3 (en) 2006-11-02

Family

ID=36569884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/005720 Ceased WO2006089150A2 (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin

Country Status (10)

Country Link
EP (1) EP1853302A2 (en)
JP (1) JP2008530239A (en)
KR (1) KR20070108909A (en)
CN (1) CN101146549A (en)
AU (1) AU2006214138A1 (en)
BR (1) BRPI0608880A2 (en)
CA (1) CA2598448A1 (en)
MX (1) MX2007010037A (en)
RU (1) RU2007134570A (en)
WO (1) WO2006089150A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101497607B (en) * 2008-01-29 2012-11-28 上海百灵医药科技有限公司 Process for synthesizing sunitinib
EP2149565A1 (en) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfoximine substituted chinazoline derivatives as immune modulators for the treatment of inflammatory and allergic diseases
EA020117B1 (en) * 2008-11-14 2014-08-29 Консерт Фармасьютикалс Инк. Substituted dioxopiperidinyl phthalimide derivaties
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
LT3575288T (en) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101478925B1 (en) * 2013-12-31 2015-01-08 아주대학교산학협력단 Pharmaceutical composition for treating or preventing cancer disease comprising proteasome inhibitor and loperamide
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108069913B (en) * 2016-11-18 2022-03-01 陕西师范大学 Bis(morpholinylalkoxy)quinazoline derivatives and their use in antitumor
PE20200303A1 (en) 2017-05-24 2020-02-06 Novartis Ag ANTIBODY PROTEINS GRAFTED WITH CYTOKINE AND METHODS OF USE IN THE TREATMENT OF CANCER
CA3119343C (en) 2018-11-13 2024-01-16 Biotheryx, Inc. Substituted isoindolinones
CN114920704B (en) * 2019-07-26 2023-11-03 暨南大学 Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application
CN111499583B (en) * 2020-05-22 2022-02-15 沈阳工业大学 Quinazoline derivative and application thereof as antitumor drug
CN112538071A (en) * 2020-11-30 2021-03-23 新乡医学院第一附属医院 Compounds useful as RAF-1 inhibitors, methods of preparation and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SONI SANDEEP ET AL: "Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide.", JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY. 2002 AUG-SEP, vol. 24, no. 6, August 2002 (2002-08-01), pages 488 - 491, XP009067555, ISSN: 1077-4114 *
STERNBERG C N: "Metastatic renal cell cancer treatments.", DRUGS OF TODAY, vol. 39, no. Suppl. C, November 2003 (2003-11-01), pages 39 - 59, XP009067549, ISSN: 0025-7656 *

Also Published As

Publication number Publication date
CN101146549A (en) 2008-03-19
JP2008530239A (en) 2008-08-07
BRPI0608880A2 (en) 2010-02-02
RU2007134570A (en) 2009-03-27
MX2007010037A (en) 2008-02-15
EP1853302A2 (en) 2007-11-14
CA2598448A1 (en) 2006-08-24
WO2006089150A2 (en) 2006-08-24
KR20070108909A (en) 2007-11-13
AU2006214138A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2006089150A3 (en) Antiangiogenic agents with aldesleukin
IL257622B (en) Methods and compositions for the treatment of persistent infections
WO2006091395A3 (en) Inhibitors of akt activity
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2006135627A3 (en) Inhibitors of akt activity
PL1765391T3 (en) Bacterial compositions for the treatment of cancer
WO2005094376A3 (en) Synergistic methods and compositions for treating cancer
WO2008070041A3 (en) Inhibitors of akt activity
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
WO2007011962A3 (en) Treatment of cancer
WO2005105113A3 (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
WO2007059108A3 (en) Substituted quinolones and methods of use
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2006024018A3 (en) Compositions for treating nociceptive pain
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2006110638A3 (en) Inhibitors of akt activity
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680009316.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2598448

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010037

Country of ref document: MX

Ref document number: 2007556337

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006214138

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3324/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006214138

Country of ref document: AU

Date of ref document: 20060217

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077021118

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006735400

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007134570

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0608880

Country of ref document: BR

Kind code of ref document: A2